Cancer genetic testing can help patients receive precise treatment, but it is expensive.
Recently, the two leading companies in the industry, Sanomics and ACT Genomics, decided to merge. In an interview with Hong Kong 01, the chairman of Sanomics and lung cancer expert Mo Shujin said that the combined company will become the largest cancer in Southeast Asia Genetic testing companies will strengthen cooperation with pharmaceutical companies and look forward to receiving sponsorships to lower the pricing of genetic testing products in the future.
+7
Sunmi is a company in the Science Park that specializes in providing cancer genetic testing services. The main service target is lung cancer patients. There are 11 products in total.
The strong point of action gene is Next generation sequencing (NGS). One product can detect multiple genes. For example, there is a product that can detect 440 cancer-related genes at the same time. The company currently has more than 10 models. Self-developed products.
Sanomics and ACT Genomics, the two major "leaders" in the cancer genetic testing industry, have completed the merger.
(Photo by He Baijia)
Lung cancer genetic testing costs 10,000 yuan after the merger, the testing volume can be doubled
Currently, Shanmi charges 10,000 yuan for cancer genetic testing products for lung cancer, while patients in public hospitals only need to pay 3,000 yuan.
Mo Shujin, chairman of Shanmi and lung cancer expert, said that the two companies are competitors themselves, but because they want to better serve patients, they recently decided to merge to become the largest cancer genetic testing company in Southeast Asia. Cooperating with international pharmaceutical companies, hoping to obtain sponsorship, the price of products can be further lowered in the future, and genetic testing technology can also be applied to clinical and scientific research.
Patients in private hospitals in Hebei public hospitals can use different technology testing platforms according to clinical conditions
Mo Shujin said that the expertise of Action Gene and Sunmi are next-generation sequencing and serum technology respectively. The merger of the two companies can broaden the service spectrum. In the future, patients in public hospitals and private hospitals can use different technology platforms according to their clinical conditions. For testing, for example, the tissue test of action genes (Tissue) can be used to diagnose the disease at first, and then serum testing can be used.
Sanomics and ACT Genomics, the two major "leaders" in the cancer genetic testing industry, have completed the merger.
(Photo by He Baijia)
The next goal is to enter Vietnam
Mo Shujin continued that Shanmi has already opened up the Thai market, and its next goal is to enter Vietnam, and an office can be opened after customs clearance in the future.
According to Chen Yaoqiang, Chief Financial Officer of Action Gene, the company has a market share of 60 to 70% in Taiwan and now has a presence in Europe.
Mo Shujin intends to develop in the Greater Bay Area: See if there are any new technologies that can be brought in first
Mo Shujin said that after the merger, the company also intends to develop in the Greater Bay Area, but it depends on the opportunity: "Look at whether there are new technologies that can be brought in first." He believes that in addition to genetic testing companies, pharmaceutical companies are also suitable for the Greater Bay Area. District development and market expansion.
He bluntly said that the rent of the Science Park is expensive, and even if the Hong Kong-Shenzhen Innovation and Technology Park is opened in Shenzhen, the rent is not cheap. He hopes that the Hong Kong government can "spend more money" to provide rent and support for start-ups.
Chen Yaoqiang pointed out that he hopes the government can promote matching and cooperation between Hong Kong companies and domestic companies.
Mo Shujin pointed out that after the company's merger, it intends to cooperate with the "Hong Kong Genome Project."
(Photo by He Baijia)
Zheng Zhigang’s SPAC and genetic testing company Prenetics merged to complete the detection of five rare bacteria in the intestines of children with autism as soon as this year.
CUHK Professor Mo Shujin's research on lung cancer treatment is honored as ``2020 Oncology Giant''
